DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector under the Medical - Care Facilities industry, and its core business is kidney dialysis. As of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the U.S. and served roughly 200,500 patients. It also provides hospital inpatient dialysis, home-based dialysis, laboratory services, integrated kidney care, ancillary services, and international dialysis operations across 585 centers in 14 countries serving about 94,500 patients.

The financial footprint of this model is telling. U.S. dialysis revenues represented approximately 86% of consolidated revenues, and the 10-K notes that nearly all non-hospital dialysis profits came from commercial payors. That concentration means the company’s economics are heavily shaped by a relatively small slice of privately insured volume rather than by government reimbursement. Net margin is 6.0%, which is thin for a service business with this scale, and ROE is -123.6%. A positive P/E alongside a deeply negative ROE usually signals a negative or very small equity base—common in capital-intensive industries that carry substantial liabilities. In plain terms, DaVita’s scale and quality ratings create operational moat, but its returns are constrained by reimbursement pressure, labor and supply costs, and a capital structure that absorbs a large portion of cash flow.

On the quality side, DaVita has led CMS’s Quality Incentive Program for the 11 most recently reported years and the Five-Star Quality Rating System for 10. That is a meaningful competitive credential in a sector where payors and regulators explicitly tie reimbursement and patient steerage to outcomes, but it should not be mistaken for pricing power in the traditional sense.

Financial posture

DaVita currently trades with an $11.8 billion market cap, a P/E of 15.8, and a beta of 0.83. The beta below 1.0 suggests the stock has historically moved less violently than the overall market, which is consistent with a healthcare services business tied to recurring patient demand and Medicare-like reimbursement schedules.

Again, the standout figures are the 6.0% net margin and the -123.6% ROE. The P/E of 15.8 implies the market is pricing the company as a mid-teens multiple business with stable earnings, but the margin leaves little room for error if costs rise or commercial payor pricing weakens. The negative ROE, combined with positive net income, points to a balance sheet where liabilities exceed book equity. This is not unusual for a heavily leased, capital-intensive care-facility operator, but it does mean investors should focus on free-cash generation and debt-serviceability alongside headline earnings. The data provided does not include a specific debt figure, so any leverage discussion should remain tied to what the numbers do show: thin net margins and a book-equity base that is currently negative.

Strategic priorities & outlook

DaVita’s most recent 10-K outlines three operational priorities. First, the company wants to “reimagine high-quality kidney care” to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities that span the entire renal care continuum, from chronic kidney disease (CKD) through end-stage kidney disease (ESKD) and into kidney transplant. Third, it is aligning itself with CMS’s Comprehensive Kidney Care Contracting (CKCC) model, which rewards delaying disease progression, promoting home dialysis when clinically appropriate, and incentivizing transplants.

Those priorities read as a deliberate shift away from pure center-based volume growth and toward value-based, longitudinal kidney care. If executed, the strategy could reduce reliance on the high-cost center visit and could improve margins over time through better patient management. However, the transition also depends on CMS model stability, data integration, and physician alignment, all of which carry execution risk. The 10-K also highlights the company’s quality leadership and its large international footprint, which together give DaVita both a domestic regulatory edge and geographic diversification, albeit with the currency and operational complexity that comes from running centers in 14 countries.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita sits in a highly regulated, reimbursement-driven corner of healthcare. The most direct macro exposure is U.S. government payment policy: Medicare and Medicaid dialysis reimbursement rates, CMS quality programs, and value-based models such as CKCC set the revenue baseline for the industry. Any change to reimbursement formulas, sequestration rules, or the structure of the Medicare Advantage benchmark would flow quickly through sector earnings.

The industry is also exposed to labor-cost inflation, because dialysis centers require trained nurses, technicians, and social workers, and wage pressure can compress already thin margins. Supply-chain risk matters: dialysis supplies, machines, and pharmaceuticals can be sourced globally, so tariffs, trade restrictions, or shipping disruptions can affect both cost and availability. Currency risk applies to the international segment, since 14-country operations generate revenues and costs in local currencies. Finally, demographic trends—aging population, rising diabetes and hypertension prevalence—are a long-term demand tailwind for dialysis services, though they also intensify the policy debate over how to manage cost growth in Medicare.

Recent developments

Recent headlines have centered on price action, options positioning, sector momentum, and ownership concentration.

• On September 3, Zocks.com asked “Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?” The article flagged weakness following the company’s most recent quarterly release.
• Also on September 3, Zocks.com ran “Do Options Traders Know Something About DaVita Stock We Don’t?,” highlighting unusual or elevated options activity around the name.
• On August 28, Zocks.com included DaVita in “4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds,” reflecting broader investor interest in outpatient and home-based care models.
• On August 27, Fool.com noted that Warren Buffett and Greg Abel quietly hold a bigger percentage of this company than any other in Berkshire Hathaway’s portfolio, with the headline explicitly pointing away from Apple or American Express.

Taken together, these items frame a stock that is drawing attention for both fundamental sector trends and ownership concentration, while still dealing with negative price momentum after a recent earnings report that technically beat estimates.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beat earnings expectations six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average 5-day price move after earnings across those quarters is 6.36%, classified as an upward drift. That average, however, masks a notable pattern: a beat has not reliably translated into a follow-through rally, and even strong quarters have produced sharply divergent next-day reactions.

The last four reports illustrate the disconnect clearly:

• August 4, 2026: EPS of $4.02 beat the $3.88 estimate by 3.6%, yet the stock fell 17.24% the next day and 21.78% over the following five days.
• May 5, 2026: EPS of $2.87 beat the $2.41 estimate by 19.1%, and the stock jumped 23.46% the next day and 27.7% over the next five days.
• February 2, 2026: EPS of $3.40 beat the $3.24 estimate by 4.9%, with the stock rising 21.17% the next day and 23.79% over five days.
• October 29, 2025: EPS of $2.51 missed the $3.17 estimate by -20.8%; the stock fell 6.17% the next day and 4.27% over five days.

The takeaway is that DaVita’s post-earnings price action is not a simple function of whether the company beats or misses. The August 2026 report shows that a modest beat can coincide with a severe drawdown when guidance, margins, commercial payor mix, or regulatory commentary disappoint. The next report is scheduled for October 28, 2026, after the close, with a consensus EPS estimate of $3.58. As of the snapshot date, the stock was at $183.99, the RSI was 44.1, and the 50-day EMA stood at $194.98—meaning the price is trading beneath a declining short-term moving average heading into the print.

For a deeper dive into the complete analyst view on DaVita—including detailed institutional ratings, consensus estimate revisions, and valuation model inputs—readers should review the full institutional verdict on the ticker.